Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Tolerability of AZD5004 in Renal Impairment
NCT06742762Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elecoglipron in type 2 diabetes mellitus (T2DM) and obesity (3 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity, Area Under the Plasma Concentration-Time Curve from Time Zero to Time of Last Quantifiable Concentration and 1 more. Started Dec 2024; status: completed.
02
Drugs
elecoglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06742762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06742762.